

## **The protooncogene Vav1 regulates murine leukemia virus-induced T-cell leukemogenesis.**

Sandra Kaminski, Oumeya Adjali, Chantal Jacquet, Johan Garaude, Anne Keriél, Adeline Lassaux, Robert Hipskind, Marc Sitbon, Naomi Taylor, Martin Villalba

► **To cite this version:**

Sandra Kaminski, Oumeya Adjali, Chantal Jacquet, Johan Garaude, Anne Keriél, et al.. The protooncogene Vav1 regulates murine leukemia virus-induced T-cell leukemogenesis.. *OncoImmunology*, Taylor & Francis, 2012, 1 (5), pp.600-608. <10.4161/onci.20225>. <inserm-00726759>

**HAL Id: inserm-00726759**

**<http://www.hal.inserm.fr/inserm-00726759>**

Submitted on 31 Aug 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# The protooncogene Vav1 regulates murine leukemia virus-induced T cell leukemogenesis

Sandra Kaminski,<sup>1,†</sup> Oumeya Adjali,<sup>1,†</sup> Chantal Jacquet,<sup>1</sup> Johan Garaude,<sup>2</sup> Anne Keriel,<sup>1</sup> Adeline Lassaux,<sup>1</sup> Robert A. Hipskind,<sup>1</sup> Naomi Taylor<sup>1</sup> and Martin Villalba<sup>2,\*</sup>

<sup>1</sup>Institut de Génétique Moléculaire de Montpellier; UMR 5535; CNRS; Montpellier, France; <sup>2</sup>INSERM; U1040; Université de Montpellier 1; UFR Médecine; Montpellier, France

<sup>†</sup>These authors contributed equally to this work.

**Key words:** Vav, T cell, leukemia, murine leukemia virus, retrovirus

Vav1 is expressed exclusively in hematopoietic cells and is required for T cell development and activation. Vav1-deficient mice show thymic hypocellularity due to a partial block during thymocyte development at the DN3 stage and between the double positive (DP) and single positive (SP) transition. Vav1 has been shown to play a significant role in several non-hematopoietic tumors but its role in leukemogenesis is unknown. To address this question, we investigated the role of Vav1 in retrovirus-induced T cell leukemogenesis. Infection of Vav1-deficient mice with the Moloney strain of murine leukemia virus (M-MuLV) significantly affected tumor phenotype without modulating tumor incidence or latency. M-MuLV-infected Vav1-deficient mice showed reduced splenomegaly, higher hematocrit levels and hypertrophic thymi. Notably, Vav1-deficient mice with M-MuLV leukemias presented with markedly lower TCR $\beta$ /CD3 levels, indicating that transformation occurred at an earlier stage of T cell development than in WT mice. Thus, impaired T cell development modulates the outcome of retrovirus-induced T cell leukemias, demonstrating a link between T cell development and T cell leukemogenesis.

## Introduction


Vav1, the first member of the Vav family to be described, is expressed exclusively in hematopoietic and trophoblast cells. Vav-family proteins share a tandem arrangement of a Dbl-homology (DH) domain followed by a pleckstrin homology (PH) domain. The DH domains of these proteins possess guanine nucleotide exchange factor (GEF) activity, which mediates GDP exchange for GTP on Rho-family GTPases, thereby causing activation of these GTPases. Some Rho proteins are overexpressed and hyperactivated in a number of human tumors.<sup>1</sup> As gain-of-function mutations in Rho family GTP binding proteins, such as those found in *ras*, are very rare in human cancers, inhibition of GTPase-activating proteins (GAPs) or expression of GEFs may account for the hyperactivation of Rho family signaling in cancer.<sup>2</sup> In fact, Vav1, similarly to other GEFs, was originally isolated as an oncogene<sup>3</sup> and has been shown to play a role in tumorigenesis of different origins.<sup>4</sup> Vav1 is aberrantly expressed in 53% of primary pancreatic adenocarcinomas due to demethylation of the gene promoter, and is associated with decreased patient survival.<sup>5</sup> Moreover, it contributes to the tumorigenic properties of neuroblastoma,<sup>6</sup> melanoma<sup>7</sup> and pancreatic cancer cells.<sup>5</sup> In the latter, the role of Vav1 is mediated by its GEF activity with a subsequent activation of Rac1, PAK1, NF $\kappa$ B and an upregulation of cyclin D1. Azathioprine, used in the treatment of lymphocytic

leukemias, is an inhibitor of nucleotide biosynthesis but also blocks Vav1-induced Rac activation.<sup>8,9</sup>

*Vav1*<sup>-/-</sup> mice are viable and fertile,<sup>10</sup> but they present with an abnormal hematopoiesis: the overall size of the thymus is reduced by 50% due to a reduction in the number of double positive (DP) thymocytes, albeit with normal numbers of double negative (DN) thymocytes. Analyses of DN thymocytes have demonstrated that there is a block between the DN3 (CD44<sup>+</sup>CD25<sup>+</sup>) and DN4 (CD44<sup>+</sup>CD25<sup>-</sup>) stages, at the  $\beta$ -selection checkpoint. This observation strongly suggests that in the absence of Vav1, pre-TCR signaling is impaired. Other steps though are impaired as well since single positive (SP) cells are reduced by approximately 10-fold in *Vav1*<sup>-/-</sup> mice and this block between DP to SP cells is exacerbated in the absence of other Vav family proteins, Vav2 and Vav3.<sup>10,11</sup> Furthermore, peripheral T cells derived from Vav1-deficient mice show a strong defect in cytoskeleton rearrangement and lipid raft organization, leading to impaired function.<sup>12-15</sup>

*Vav1*<sup>-/-</sup>, but not *Vav2*<sup>-/-</sup> or *Vav3*<sup>-/-</sup>, mice are prone to developing CD3<sup>+</sup> lymphoblastic lymphoma-like tumors with increasing age, with 30% of mice dying as a consequence of this disease before 1 y.<sup>16</sup> Retroviruses of the murine leukemia virus (MuLV) family promote leukemogenesis mainly by insertional activation of proto-oncogene expression.<sup>17</sup> Viral enhancers act on proximal as well as distal promoters with the latter mediated via interactions facilitated by chromatin looping (reviewed in ref. 18).

\*Correspondence to: Martin Villalba; Email: martin.villalba@inserm.fr  
Submitted: 03/15/12; Accepted: 03/30/12  
<http://dx.doi.org/10.4161/onci.20225>



**Figure 1.** Survival and tumor incidence in mice after M-MuLV infection. *Vav1*<sup>+/+</sup> (n = 44), *Vav1*<sup>+/-</sup> (n = 72) and *Vav1*<sup>-/-</sup> (n = 48) mice were infected with M-MuLV. The graph shows the cumulative incidence of leukemia based on enlarged lymphoid organs and hematocrit levels.

Thus, integrated proviruses can affect many genes<sup>19</sup> and induce leukemia in a multistep/multigene fashion, rather than through a unique mutation in a specific gene.

Because of the important role of *Vav1* in tumorigenesis and T cell development, we infected newborn mice with the Moloney strain of MLV (M-MuLV), which commonly induces leukemia/lymphoma of T cell origin.<sup>17,20-24</sup> In neonatal mice, M-MuLV-induced leukemogenesis is particularly efficient, in part due to the absence of an antiviral immune response through tolerance-inducing mechanisms.<sup>17</sup> As the potential role of an antiviral immune response is limited in this model, we used neonatal WT and *Vav1*<sup>-/-</sup> mice to assess the role of *Vav1* in the development of retrovirus-induced leukemias. While the absence of *Vav1* did not affect disease incidence or latency, the phenotype of leukemic cells in the thymus and periphery were distinct.

## Results

**Development of leukemias in WT and *Vav1*<sup>-/-</sup> mice following M-MuLV inoculation.** To investigate the role of *Vav1* in T cell leukemogenesis, we inoculated newborn *Vav1*<sup>+/+</sup>, *Vav1*<sup>+/-</sup> and *Vav1*<sup>-/-</sup> mice intraperitoneally with M-MuLV, a retrovirus known to induce the development of T lymphomas.<sup>17,20-23</sup> There was no significant difference in M-MuLV-induced disease incidence or latency with approximately 50% of mice developing clinical signs of disease by day 115 post-infection (Fig. 1). By day 200 post-infection, all mice had developed leukemia.


M-MuLV-induced leukemia is characterized by increases in spleen size and, to a lesser extent, the thymus.<sup>17,25</sup> Despite similar survival rates, *Vav1*<sup>-/-</sup> mice presented with clinical characteristics that distinguished them from *Vav1*<sup>+/+</sup> and *Vav1*<sup>+/-</sup> mice (Fig. 2). The hematocrits of healthy mice of all genotypes ranged between 45 to 50% (data not shown). M-MuLV-inoculated *Vav1*<sup>+/+</sup> and *Vav1*<sup>+/-</sup> mice presented with significantly lower hematocrits,

ranging from 40 to 42% (Fig. 2A). Notably, the hematocrits in M-MuLV-inoculated *Vav1*<sup>-/-</sup> mice with leukemias were significantly higher (mean of 47%,  $p < 0.001$ ), suggesting that erythropoiesis was less affected in these mice than in their WT counterpart or that they showed a lower percentage of leukemic T cells in the periphery.

Splenic cellularity in healthy mice of all genotypes was equivalent with a weight of approximately 0.08 g (Fig. 2B). Upon M-MuLV-induced leukemogenesis, *Vav1*<sup>+/+</sup> and *Vav1*<sup>+/-</sup> mice developed severe splenomegaly (10-fold weight increase) that correlated with increased cellularity (Fig. 2B and C). While splenomegaly was also detected in M-MuLV-infected *Vav1*<sup>-/-</sup> mice, their spleens were significantly smaller and showed decreased cellularity as compared with leukemic *Vav1*<sup>+/+</sup> and *Vav1*<sup>+/-</sup> mice (Fig. 2B and C).

Under conditions of M-MuLV-induced leukemia, *Vav1*<sup>+/+</sup> and *Vav1*<sup>+/-</sup> mice showed small increases in thymic size (Fig. 2D). However, in *Vav1*<sup>-/-</sup> mice, which under normal conditions have reduced thymic cellularity due to a lower number of DP cells,<sup>11</sup> M-MuLV-induced leukemia resulted in a massive increase in the size of the thymus (Fig. 2B and D). The thymi of *Vav1*<sup>-/-</sup> infected mice often invaded the entire thoracic cavity and indeed, these mice often suffered from respiratory problems during the latter stages of disease.

**Distinct thymocyte profiles in *Vav1*<sup>+/+</sup> and *Vav1*<sup>-/-</sup> mice with M-MuLV-induced leukemia.** M-MuLV-induced T cell leukemogenesis is often associated with the expansion and accumulation of thymocytes with an immature phenotype.<sup>17,25</sup> To study the phenotype of thymocytes accumulating in the different mice cohorts, we first assessed the CD4/CD8 profiles. While profiles of thymocytes from infected mice showed some variability, they differed significantly from those of healthy mice. CD4/CD8 staining from individual mice is presented in Figure 3A. The majority of lymphomagenic thymi from leukemic *Vav1*<sup>+/+</sup> mice harbored a high percentage of CD4-expressing cells, as also reported following infection with the radiation leukemia virus (RadLV<sup>26</sup>). In healthy *Vav1*<sup>-/-</sup> mice, the percentages of DN and SP thymocytes were modulated, with significantly higher levels of the former ( $p < 0.05$ ) and lower levels of the latter ( $p < 0.05$ ; Fig. 3A and B and reviewed in ref. 11). Leukemia development in *Vav1*<sup>-/-</sup> mice was associated with higher variability; approximately half the mice harbored >40% single positive CD4 cells (SP4) while the remainder harbored <20% SP4 cells (Fig. 3A and B). To study the differentiation state of these SP4 cells, we monitored TCR $\beta$  expression. In agreement with previously published data in reference 27, thymi of healthy *Vav1*<sup>-/-</sup> mice had a significantly lower level of TCR $\beta$ -hi cells (Fig. 3C and Table 1), indicative of an immature stage of thymopoiesis as compared with WT mice where the majority of cells were mature TCR $\beta$ -hi SP4 thymocytes (49% and 73%, respectively). While TCR $\beta$  expression remained elevated on SP4 thymocytes in leukemic *Vav1*<sup>+/+</sup> mice, it was undetectable on the vast majority of SP4 thymocytes from *Vav1*<sup>-/-</sup> lymphomagenic thymi. Altogether, our results indicate that lymphomagenic thymocytes from *Vav1*<sup>-/-</sup> mice have a more immature phenotype than those present in the WT counterpart.




**Figure 2.** Phenotype of M-MuLV-infected mice. Mice described in Figure 1 were analyzed for tumor phenotype. (A) Hematocrits in the different mice populations were monitored one day before euthanasia. (B) Spleen and thymus cellularity in M-MuLV-infected mice. (C) Spleen weights in different mice populations. (D) Size of thymi in different mice populations. Data were evaluated using Student's t-test: \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

Furthermore, there was a significant increase in DN thymocytes in lymphomagenic thymi from both WT and *Vav1*<sup>-/-</sup> mice (Fig. 3). As *Vav1*<sup>-/-</sup> mice have a partial block between DN3 and DN4 thymocyte stages (Fig. 4 and reviewed in ref. 11), it was of interest to determine whether leukemogenesis would result in the accumulation of distinct DN populations in WT and *Vav1*<sup>-/-</sup> mice. The majority of DN cells in leukemic WT mice had a CD44<sup>+</sup>CD25<sup>-</sup> (DN1) phenotype, while the DN profile in leukemic *Vav1*<sup>-/-</sup> mice revealed significantly increased percentages of CD44<sup>+</sup>CD25<sup>+</sup> (DN3) and CD44<sup>+</sup>CD25<sup>-</sup> (DN4) cells. Thus, early stages of thymopoiesis are disrupted by M-MuLV-induced leukemia, in both WT and *Vav1*<sup>-/-</sup> mice, but the absence of *Vav1* significantly affects the development of lymphomagenic thymi.

**Age- and leukemia-mediated changes in the cell cycle entry of *Vav1*<sup>+/+</sup> and *Vav1*<sup>-/-</sup> thymocytes.** While the differentiation state of WT and *Vav1*<sup>-/-</sup> thymocytes in adult mice have long been known to be distinct,<sup>10</sup> the partition of thymocytes of different developmental stages during the newborn period is not known. This is of importance in the context of the present studies because the mice were infected with M-MuLV at 3 d of age. Furthermore,

given that M-MuLV infection targets proliferating cells, it was of interest to assess the cell cycle entry of different thymocyte populations. The percentage of DP thymocytes slightly decreased in WT mice between 3 d of age (the time point of M-MuLV inoculation) and 2 mo of age (Fig. 5A) whereas it was not statistically different in *Vav1*<sup>-/-</sup> mice. While the presence of SP4 and SP8 thymocytes augmented with age, they remained significantly lower in *Vav1*<sup>-/-</sup> than WT mice.

The entry of thymocytes into cell cycle, was monitored as a function of Ki67 expression, a protein upregulated during mid G<sub>1</sub> phase. The percentage of Ki67<sup>+</sup> cells within the DP thymocyte subset was not modulated by either age or the presence of *Vav1* (Fig. 5A). The percentages of Ki67<sup>+</sup> DN cells decreased with age but this phenomenon was observed in both WT and *Vav1*<sup>-/-</sup> mice. Notably, within the SP8 population, the relative proportion of Ki67<sup>+</sup> cells was higher during the newborn period, with greater than 50% of this subset expressing Ki67 in neonatal *Vav1*<sup>-/-</sup> mice. However, the total numbers of Ki67<sup>+</sup> SP8 thymocytes were still lower in *Vav1*<sup>-/-</sup> mice due to the relative paucity of this population. Almost identical data were obtained in the SP4 population. Importantly, the increased



**Figure 3.** Thymocyte populations in M-MuLV infected mice. (A) Flow cytometry analysis of thymi from control and M-MuLV infected mice. Cells were stained with anti-CD4 and anti-CD8 antibodies to distinguish CD4<sup>-</sup>/CD8<sup>-</sup> (DN), CD4<sup>+</sup>/CD8<sup>+</sup> (DP), CD4<sup>+</sup>/CD8<sup>-</sup> (CD4<sup>+</sup>) and CD4<sup>-</sup>/CD8<sup>+</sup> (CD8<sup>+</sup>) populations. (B) Percentages of DN, DP, CD4<sup>+</sup> and CD8<sup>+</sup> from representative populations of mice (Vav1<sup>+/+</sup> control (n = 6); Vav1<sup>-/-</sup> control (n = 6); Vav1<sup>+/+</sup> M-MuLV (n = 4); Vav1<sup>-/-</sup> M-MuLV (n = 9)). The numbers in brackets reflect the mice whose plots are depicted in (A). (C) Representative histograms showing TCRβ expression in the CD4<sup>+</sup>/CD8<sup>-</sup> subset of different mice populations. Data were evaluated using Student's t-test: \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001.

**Table 1.** Low surface TCRβ expression on CD4<sup>+</sup> thymocytes in Vav1<sup>-/-</sup> mice with M-MuLV-induced leukemias


		Control		M-MuLV	
TCRβ		Vav <sup>+/+</sup>	Vav <sup>-/-</sup>	Vav <sup>+/+</sup>	Vav <sup>-/-</sup>
CD4 low	average ± SEM (%)	27.1 ± 4.7	17.7 ± 2.2	58.1 <sup>(1)</sup> ± 13.8	1.2 <sup>(2)(3)</sup> ± 0.3
CD4 high		79.8 ± 15.7	64.1 ± 8.3	64.9 ± 15.3	7.17 <sup>(2)(3)</sup> ± 6.6

Thymocytes from control or M-MuLV infected mice were stained as described in Figure 3. Within the SP4 gate (CD4<sup>+</sup>CD8<sup>-</sup>), TCRβ expression was assessed. The mean percentages ± SEM of SP4 cells expressing TCRβ are presented. Data were evaluated using Student's t-test and TCRβ expression within the SP4 thymocyte subset in infected Vav1<sup>-/-</sup> mice was significantly lower than that detected in uninfected WT mice, uninfected Vav1<sup>-/-</sup> mice and WT infected mice. p < 0.05 compare with non infected WT mice (1), compare with WT mice (2) and compare with non infected Vav1<sup>-/-</sup> mice.

percentages of Ki67<sup>+</sup> cells within the DN and immature SP4 and SP8 thymocyte populations of Vav1<sup>-/-</sup> mice were associated with the less mature phenotype of leukemic cells in M-MuLV-induced mice as compared with their wild-type counterpart (Figs. 3 and 4).

Newborn Vav1<sup>-/-</sup> mice showed a higher percentage of Ki67<sup>+</sup> DN cells as compared with WT mice, a feature that was also observed in adult mice (Fig. 5B and reviewed in ref. 27). However, the majority of Ki67<sup>+</sup> cells were found in the DP

subpopulation, which is the largest population present in both genotypes. Interestingly though, we did not observe any increase in DP cells in lymphomagenic thymi of adult mice (Fig. 3), suggesting that the virus did not target this population, or, alternatively, that infected cells underwent differentiation during the transformation process. SP4 cells, which represented the most abundant population in lymphomagenic thymi from both genotypes, were only rarely Ki67<sup>+</sup> (Fig. 5B). Given that MuLV infection requires mitosis, these data strongly suggest it is not the SP4



**Figure 4.** Impaired thymocyte development in *Vav1*<sup>-/-</sup> M-MuLV mice. (A) Flow cytometric analysis of thymi from control and M-MuLV infected mice. Cells were stained with CD44 and CD25 antibodies to distinguish DN1 (CD44<sup>+</sup>/CD25<sup>-</sup>), DN2 (CD44<sup>+</sup>/CD25<sup>+</sup>), DN3 (CD44<sup>-</sup>/CD25<sup>+</sup>) and DN4 (CD44<sup>-</sup>/CD25<sup>-</sup>) subsets within the CD4<sup>+</sup>CD8<sup>-</sup> population. (B) Percentages of DN1, DN2, DN3 and DN4 from representative populations of mice (*Vav1*<sup>+/+</sup> control (n = 6); *Vav1*<sup>-/-</sup> control (n = 6); *Vav1*<sup>+/+</sup> M-MuLV (n = 4); *Vav1*<sup>-/-</sup> M-MuLV (n = 9)). The numbers in brackets reflect the mice whose plots are depicted in (A). Data were evaluated using Student's t-test: \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001.


population itself that was targeted by the virus but a cell at an earlier stage of differentiation.

**Phenotype of peripheral leukemic cells in *Vav1*<sup>+/+</sup> and *Vav1*<sup>-/-</sup> mice.** M-MuLV-induced leukemias are first produced in the thymus but there is also a peripheral involvement during later stages of the disease.<sup>17,21-23</sup> In order to characterize the phenotype of lymphomagenic cells in the periphery, we studied the expression of several cell markers in splenocytes from M-MuLV-inoculated mice. In WT as well as *Vav1*<sup>-/-</sup> leukemic mice, there was an expected decrease in the percentage of CD19<sup>+</sup> B cells due to the presence of leukemic cells. As *Vav1*<sup>-/-</sup> mice have decreased percentages of peripheral T cells under normal conditions,<sup>10</sup> the relative percentage of CD19<sup>+</sup> cells filling this niche<sup>28,29</sup> was initially increased. Somewhat surprisingly though, there was a decreased percentage of CD3<sup>+</sup> cells in leukemic *Vav1*<sup>-/-</sup> mice (Fig. 6A). As leukemic cells generally lacked TCR $\beta$  expression *Vav1*<sup>-/-</sup> mice (Fig. 3), we assessed whether these peripheral TCR $\beta$ <sup>-</sup> CD3<sup>-</sup> cells expressed CD4 or CD8 lineage markers. Indeed, there were more than 4-fold increases in both CD3<sup>-</sup>CD4<sup>+</sup> and CD3<sup>-</sup>CD8<sup>+</sup> cells in leukemic *Vav1*<sup>-/-</sup> mice (from >5% to 15–20% of all splenocytes, Fig. 6B). Interestingly, the increase in these immature CD3<sup>-</sup> cells was modest in WT mice with leukemias (2–4% to approximately 8%; Fig. 6B). Furthermore, mature CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> were not significantly increased in leukemic WT mice and in fact, were decreased in the *Vav1*<sup>-/-</sup> mice. Thus, in *Vav1*<sup>-/-</sup> mice with leukemias, splenocytes as well as thymocytes harbor an immature CD3<sup>-</sup> T cell phenotype. Altogether, CD3<sup>+</sup> leukemias were significantly decreased in *Vav1*<sup>-/-</sup> mice as compared with WT mice following infection with M-MuLV.

## Discussion

In this report, we investigated whether a protein that plays an essential role in lymphopoiesis also influences leukemogenesis. *Vav1* strongly affects the T cell compartment without modulating other lineages and as such, it was of interest to selectively induce T cell leukemias. To this end, we used the M-MuLV retrovirus that lacks oncogenes and induces T cell lymphomas with a latency of 3–4 mo.<sup>17</sup> Here, we report that the presence of *Vav1* regulates M-MuLV-induced T cell leukemogenesis. *Vav1*<sup>+/+</sup> mice infected with M-MuLV develop the typical disease, characterized by a decrease in hematocrit, a modest enlargement of the thymus and a significant splenomegaly (Figs. 1 and 2 and reviewed in ref. 17 and 20–24). At the cellular level, leukemic cells predominantly expressed markers associated with T cell maturation such as CD3 and TCR $\beta$  (Figs. 3 and 4). Notably, in the absence of *Vav1*, infection with M-MuLV resulted in leukemias characterized by higher hematocrits, massive thymus enlargement and a more modest splenomegaly. Furthermore, the leukemic phenotypes in the thymus as well as the periphery differed; with a significantly more immature phenotype in *Vav1*<sup>-/-</sup> as compared with WT mice.

Induction of tumors by M-MuLV presumably results from infection of a target cell and a series of subsequent tumor progression events. Target cells for M-MuLV are early cells committed to the T cell lineage and they differentiate to various stages in T-cell differentiation before the final transforming event.<sup>21-23</sup> The identity of the infected cells during the early stages of leukemogenesis remains unknown. The most




**Figure 5.** Cell cycle entry of different thymocyte populations. Thymocytes were stained with the corresponding antibodies to identify CD4<sup>+</sup>/CD8<sup>-</sup> (DN), CD4<sup>+</sup>/CD8<sup>+</sup> (DP), CD4<sup>+</sup>/CD8<sup>-</sup> (SP4) and CD4<sup>+</sup>/CD8<sup>+</sup> (SP8) cells and with an anti-Ki67 antibody to analyze cell cycle entry. (A) The total percentages of cells and the percentages of Ki67<sup>+</sup> cells in the different populations are shown in 3-d old (white bars) and adult (black bars) mice of both genotypes. (B) Comparative analysis of Ki67 expression in the different populations between *Vav1*<sup>-/-</sup> and wild-type mice. Data represent the mean percentages ± SEM of three independent experiments with n = 3 mice per group. Data were evaluated using Student's t-test: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

immature population in the thymus is the DN subset, which is subdivided into different stages: CD44<sup>+</sup>CD25<sup>-</sup> (DN1), the CD44<sup>+</sup>CD25<sup>+</sup> (DN2) stage during which TCRβ rearrangements are initiated, the CD44<sup>-</sup>CD25<sup>+</sup> (DN3) stage associated with initial CD3 expression and selection for productive TCRβ rearrangements, followed by the CD44<sup>-</sup>CD25<sup>-</sup> (DN4) stage of the TCRβ locus. The expression of a functional pre-TCR complexes leads to the DN4 stage and DP cells, expressing the CD4 and CD8 coreceptors, undergo TCRα rearrangements and express a mature TCRαβ complex. After positive and negative selection these cells become SP thymocytes with the maximal expression of CD3. The CD4<sup>+</sup> thymocyte population increased in mice developing M-MuLV-induced leukemias. Importantly though, in *Vav1*<sup>-/-</sup> mice, leukemogenesis resulted in a massive accumulation in DN cells. Moreover, the DN population was altered in both mice strains, suggesting that these cells may represent a preleukemic state. As DN4 cells were the major DN population in infected *Vav1*<sup>-/-</sup> thymi, it is likely that leukemic cells overpassed the *Vav1* requirement at the DN3 to DN4 transition (Fig. 4) or alternatively, were infected at that stage as they show a proliferative burst.<sup>30,31</sup>

Because the thymocyte population that increased in lymphomagenic thymi was CD4<sup>+</sup>, we compared the expression of two T cell differentiation markers in leukemic *Vav1*<sup>+/+</sup> and *Vav1*<sup>-/-</sup> CD4<sup>+</sup> cells; CD3 and TCRβ. We found that CD4<sup>+</sup> cells derived from leukemic *Vav1*<sup>-/-</sup> mice lacked expression of TCRβ (Fig. 3 and Table 1), even if CD4 was expressed at high levels. In agreement with the thymus data, the vast majority of peripheral leukemic cells in *Vav1*<sup>-/-</sup> mice were CD3<sup>-</sup>. We favor a model in which, in the absence of *Vav1*, the pre-leukemic T cells fail to properly differentiate keeping their immature phenotype.

*Vav1*<sup>-/-</sup>, but not *Vav2*<sup>-/-</sup> or *Vav3*<sup>-/-</sup>, mice are prone to developing lymphoblastic lymphoma-like tumors during aging.<sup>16</sup> It is possible that in old animals, exhaustion of T cell activity



**Figure 6.** Analysis of splenocyte populations in M-MuLV infected mice. (A) Expression of CD3, CD19, CD4 and CD8 in splenocytes (Vav<sup>+/+</sup> control (n = 8); Vav<sup>-/-</sup> control (n = 8); Vav<sup>+/+</sup> M-MuLV (n = 36); Vav<sup>-/-</sup> M-MuLV (n = 46)) were assessed by flow cytometry and bar graphs presenting the mean percentages ± SEM of splenocytes expressing CD3 and CD19 are shown. (B) Graphs presenting the mean percentages ± SEM of splenocytes expressing CD4 and CD8 in the absence or presence of surface CD3 are shown. Data were evaluated using Student's t-test: \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001.

and increased pressure for T cells to divide could be responsible for the increase in tumorigenesis. However, the phenotype of “spontaneous” lymphomas in aging *Vav1*<sup>-/-</sup> mice is similar to that detected in aging *wt* mice. This might suggest that it is the increased homeostatic-drive proliferation occurring in lymphopenic *Vav1*<sup>-/-</sup> mice that contributes to leukemia formation in a spontaneous setting. In contrast, under the conditions reported here, M-MuLV clearly favored the transformation of a more immature T cell precursor. Compare with our results (Fig. 2), aging leukemic *Vav1*<sup>-/-</sup> mice do not show massive thymic enlargement.<sup>16</sup> It could be that initial leukemic cells are produced in a more mature phenotype in aging mice, which do not localize in the thymus. An alternative explanation is that aging thymi lose partially their functions,<sup>32</sup> allowing tumor cells to exit the thymus even at the first stages of the disease.

*Vav1* is misexpressed and plays a significant role in different kind of non-hematopoietic tumors,<sup>5,6</sup> including melanoma cell invasion.<sup>7</sup> However, gain-of-function mutations in the *Vav1* gene have not yet been found in human tumors of hematopoietic origin. Perhaps primary cells select against such mutations. In fact, a recent study on mice has shown that oncogenic *Vav1* expression inhibits hematopoietic stem cell engraftment and cell expansion *in vitro* by inducing apoptosis.<sup>33</sup>

Studies of M-MuLV-induced leukemia have provided insights into the multistep process of leukemogenesis. The fact that the disease occurs with a moderate, predictable latency has allowed identification of the virological and physiological steps that occur during preleukemic stages and during tumor progression. Some of the principles uncovered are likely to be applicable to the development of neoplasms in other species, including humans. This model is complex and often involves activation of more than a specific oncogenic pathway. Human T cell leukemia virus (HTLV-1), the etiologic agent of adult T cell leukemia (ATL), can be transmitted by breastfeeding but only leads to the development of the disease in 2–5% of the infected infants and only after latency periods of 20 to 60 y.<sup>34</sup> Transformed ATL cells are generally CD4<sup>+</sup> and it is interesting to note that in our WT mice,

the majority of M-MuLV-induced leukemias were of the CD4 phenotype. Some ATL, as well as mice harboring the Tax gene of HTLV-1, present with an immature CD4<sup>+</sup>CD8<sup>-</sup> phenotype.<sup>35</sup> It will be of interest to assess *Vav1* expression in these leukemias, which could correlate with the developmental status of the leukemic cells.

All together our data suggest that the proteins involved in T cell differentiation also regulate the development of T cell leukemias. Induction of tumors by a retrovirus results from infection of a target cell and a series of subsequent tumor progression events. The data presented here suggest that the target cells wherein M-MuLV promotes tumor formation differ in the presence and absence of *Vav1*. In *Vav1* deficient mice, impaired T cell development during the selection processes favors the emergence of a different tumor phenotype.

## Materials and Methods

**Mice.** *Vav1*<sup>-/-</sup> mice in the 129 SV background, a generous gift from Dr. V. Tybulewicz, have been previously described in reference 12, and were maintained under the same conditions as 129 SV mice. All animal experiments were performed according to the guidelines and regulations of the Centre National de la Recherche Scientifique.

**Virus inoculation and clinical evaluation of mice.** *Vav1*<sup>-/-</sup>, *Vav1*<sup>+/+</sup> and 129 SV mice, 18 to 72 h old, were inoculated intraperitoneally with 10<sup>5</sup> foci forming units (FFU) of M-MuLV in 50 μL as previously described in reference 20. Mice were monitored for gross organ enlargement by palpation under Forene® (isofurane, Abbott France) anesthesia. Hematocrits, expressed as the percentage of erythrocytes in the blood volume, were measured in retroorbital vein blood samples collected in heparinized capillary tubes. Fifty days after infection, hematocrits were monitored regularly at approximately 20-d intervals. After sacrifice of moribund animals, spleens were weighed and thymic size was scored from normal, to clearly enlarge (medium), to invading the whole thoracic cavity (large).



**Immunophenotyping and flow cytometry analyses.** Splenocytes and thymocytes were stained with the appropriate conjugated  $\alpha$ CD8,  $\alpha$ CD4,  $\alpha$ CD3,  $\alpha$ CD25,  $\alpha$ CD44, Ki-67, TCR $\beta$  (PharMingen, San Diego, CA),  $\alpha$ CD3 and  $\alpha$ CD19 (Immunotech, Marseille, France) mouse monoclonal Abs, as indicated. Stained cells were analyzed by flow cytometry using a FACSCalibur (Becton Dickinson, San Jose, CA) and analyses were performed with CellQuest (Becton Dickinson) or FlowJo (Tree Star, Ashland, Oregon) software as previously described in reference 36 and 37.

**Statistical analysis.** All results were analyzed by an unpaired Student's t-test.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### References

1. Sahai E, Marshall CJ. RHO-GTPases and cancer. *Nat Rev Cancer* 2002; 2:133-42; PMID:12635176; <http://dx.doi.org/10.1038/nrc725>.
2. Bustelo XR. Regulatory and signaling properties of the Vav family. *Mol Cell Biol* 2000; 20:1461-77; PMID:10669724; <http://dx.doi.org/10.1128/MCB.20.5.1461-77.2000>.
3. Katzav S, Martin-Zanca D, Barbacid M. *vav*, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. *EMBO J* 1989; 8:2283-90; PMID:2477241.
4. Lazer G, Katzav S. Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy? *Cell Signal* 2011; 23:969-79; PMID:21044680; <http://dx.doi.org/10.1016/j.cell-sig.2010.10.022>.
5. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. *Cancer Cell* 2005; 7:39-49; PMID:15652748; <http://dx.doi.org/10.1016/j.ccr.2004.11.024>.
6. Hornstein I, Pikarsky E, Groysman M, Amir G, Peylan-Ramu N, Katzav S. The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. *J Pathol* 2003; 199:526-33; PMID:12635144; <http://dx.doi.org/10.1002/path.1314>.
7. Bartolomé RA, Molina-Ortiz I, Samaniego R, Sánchez-Mateos P, Bustelo XR, Teixidó J. Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. *Cancer Res* 2006; 66:248-58; PMID:16397238; <http://dx.doi.org/10.1158/0008-5472.CAN-05-2489>.
8. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. *J Immunol* 2006; 176:640-51; PMID:16365460.
9. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4<sup>+</sup> T lymphocytes. *J Clin Invest* 2003; 111:1133-45; PMID:12697733.
10. Tybulewicz VL. Vav-family proteins in T-cell signalling. *Curr Opin Immunol* 2005; 17:267-74; PMID:15886116; <http://dx.doi.org/10.1016/j.coi.2005.04.003>.
11. Tybulewicz VL, Ardouin L, Prisco A, Reynolds LF. Vav1: a key signal transducer downstream of the TCR. *Immunol Rev* 2003; 192:42-52; PMID:12670394; <http://dx.doi.org/10.1034/j.1600-065X.2003.00032.x>.

#### Acknowledgements

We thank the members of the animal facility at the IGMM. This work was supported by the program "Chercheur d'avenir" from the Region Languedoc-Roussillon (M.V.), a scientific program from the "Communauté de Travail des Pyrénées" (CTPP10/09 to M.V.), the Association pour la Recherche contre le Cancer (M.V. and N.T.), the Fondation pour la Recherche Médicale (M.V.), a grant FEDER Objectif competitivite (M.V.), a grant from European Community Program SUDOE (M.V.) and the FP7 integrated project grant ATTACK (N.T.) and a fellowship from La Ligue Nationale Contre le Cancer (S.K.).

12. Villalba M, Bi K, Hu J, Altman Y, Bushway P, Reits E, et al. Translocation of PKC[theta] in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C. *J Cell Biol* 2002; 157:253-63; PMID:11956228; <http://dx.doi.org/10.1083/jcb.200201097>.
13. Villalba M, Bi K, Rodriguez F, Tanaka Y, Schoenberger S, Altman A. Vav1/Rac-dependent actin cytoskeleton reorganization is required for lipid raft clustering in T cells. *J Cell Biol* 2001; 155:331-8; PMID:11684704; <http://dx.doi.org/10.1083/jcb.200107080>.
14. Holsinger LJ, Graef IA, Swat W, Chi T, Bautista DM, Davidson L, et al. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. *Curr Biol* 1998; 8:563-72; PMID:9601640; [http://dx.doi.org/10.1016/S0960-9822\(98\)70225-8](http://dx.doi.org/10.1016/S0960-9822(98)70225-8).
15. Fischer KD, Kong YY, Nishina H, Tedford K, Marengère LE, Koziarzki I, et al. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. *Curr Biol* 1998; 8:554-62; PMID:9601639; [http://dx.doi.org/10.1016/S0960-9822\(98\)70224-6](http://dx.doi.org/10.1016/S0960-9822(98)70224-6).
16. Ruiz S, Santos E, Bustelo XR. The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis. *PLoS One* 2009; 4:8229; PMID:20011522; <http://dx.doi.org/10.1371/journal.pone.0008229>.
17. Fan H. Leukemogenesis by Moloney murine leukemia virus: a multistep process. *Trends Microbiol* 1997; 5:74-82; PMID:9108934; [http://dx.doi.org/10.1016/S0966-842X\(96\)10076-7](http://dx.doi.org/10.1016/S0966-842X(96)10076-7).
18. West AG, Fraser P. Remote control of gene transcription. *Hum Mol Genet* 2005; 14:101-11; PMID:15809261; <http://dx.doi.org/10.1093/hmg/ddi104>.
19. Uren AG, Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. *Oncogene* 2005; 24:7656-72; PMID:16299527; <http://dx.doi.org/10.1038/sj.onc.1209043>.
20. Garaude J, Kaminski S, Charni S, Aguilò JI, Jaquet C, Plays M, et al. Impaired anti-leukemic immune response in PKCtheta-deficient mice. *Mol Immunol* 2008; 45:3463-9; PMID:18462800; <http://dx.doi.org/10.1016/j.molimm.2008.03.016>.
21. Lazo PA, Klein-Szanto AJ, Tschlis PN. T-cell lymphoma lines derived from rat thymomas induced by Moloney murine leukemia virus: phenotypic diversity and its implications. *J Virol* 1990; 64:3948-59; PMID:2196385.
22. Clark SS, Chen E, Fizzotti M, Witte ON, Malkovska V. BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. *J Virol* 1993; 67:6033-46; PMID:8396667.
23. Ott DE, Keller J, Sill K, Rein A. Phenotypes of murine leukemia virus-induced tumors: influence of 3' viral coding sequences. *J Virol* 1992; 66:6107-16; PMID:1326661.
24. Audit M, Déjardin J, Hohl B, Sidobre C, Hope TJ, Mougel M, et al. Introduction of a cis-acting mutation in the capsid-coding gene of moloney murine leukemia virus extends its leukemogenic properties. *J Virol* 1999; 73:10472-9; PMID:10559365.
25. Storch TG, Arnstein P, Manohar V, Leiserson WM, Chused TM. Proliferation of infected lymphoid precursors before Moloney murine leukemia virus-induced T-cell lymphoma. *J Natl Cancer Inst* 1985; 74:137-43; PMID:3871491.
26. Sen-Majumdar A, Weissman IL, Hanstean G, Marian J, Waller EK, Lieberman M. Radiation leukemia virus-induced thymic lymphomas express a restricted repertoire of T-cell receptor V beta gene products. *J Virol* 1994; 68:1165-72; PMID:8289345.
27. Raberger J, Boucheron N, Sakaguchi S, Penninger JM, Ellmeier W. Impaired T-cell development in the absence of Vav1 and Itk. *Eur J Immunol* 2008; 38:3530-42; PMID:19009524; <http://dx.doi.org/10.1002/eji.200838388>.
28. Doody GM, Bell SE, Vigorito E, Clayton E, McAdam S, Tooze R, et al. Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. *Nat Immunol* 2001; 2:542-7; PMID:11376342; <http://dx.doi.org/10.1038/88748>.
29. Tedford K, Nitschke L, Girkontaite I, Charlesworth A, Chan G, Sakk V, et al. Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. *Nat Immunol* 2001; 2:548-55; PMID:11376343; <http://dx.doi.org/10.1038/88756>.
30. Tourigny MR, Mazel S, Burtrum DB, Petrie HT. T cell receptor (TCR)-beta gene recombination: dissociation from cell cycle regulation and developmental progression during T cell ontogeny. *J Exp Med* 1997; 185:1549-56; PMID:9151892; <http://dx.doi.org/10.1084/jem.185.9.1549>.
31. Hoffman ES, Passoni L, Crompton T, Leu TM, Schatz DG, Koff A, et al. Productive T-cell receptor beta-chain gene rearrangement: coincident regulation of cell cycle and clonality during development in vivo. *Genes Dev* 1996; 10:948-62; PMID:8608942; <http://dx.doi.org/10.1101/gad.10.8.948>.
32. Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein B. Gain and loss of T cell subsets in old age—age-related reshaping of the T cell repertoire. *J Clin Immunol* 2011; 31:137-46; PMID:21243520; <http://dx.doi.org/10.1007/s10875-010-9499-x>.
33. Gu Y, Siefring JE, Wang L, Chae HD, Bailey JR, Zheng Y. Oncogenic Vav1 induces Rac-dependent apoptosis via inhibition of Bcl-2 family proteins and collaborates with p53 deficiency to promote hematopoietic progenitor cell proliferation. *Oncogene* 2006; 25:3963-72; PMID:16474842; <http://dx.doi.org/10.1038/sj.onc.1209427>.

34. Takatsuki K, Yamaguchi K, Kawano F, Hattori T, Nishimura H, Tsuda H, et al. Clinical diversity in adult T-cell leukemia-lymphoma. *Cancer Res* 1985; 45:4644-5; PMID:2861896.
35. Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. *Nat Med* 2006; 12:466-72; PMID:16550188; <http://dx.doi.org/10.1038/nm1389>.
36. Charni S, Aguiló JI, Garaude J, de Bettignies G, Jacquet C, Hipskind RA, et al. ERK5 knockdown generates mouse leukemia cells with low MHC class I levels that activate NK cells and block tumorigenesis. *J Immunol* 2009; 182:3398-405; PMID:19265117; <http://dx.doi.org/10.4049/jimmunol.0803006>.
37. Charni S, de Bettignies G, Rathore MG, Aguiló JI, van den Elsen PJ, Haouzi D, et al. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. *J Immunol* 2010; 185:3498-503; PMID:20729331; <http://dx.doi.org/10.4049/jimmunol.1001250>.